Editor: What To Know
- Cardiovascular Systems, a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that a new article published in the Journal of Medical Economicsreviews the two-year PAD-related health care costs of patients enrolled in the LIBERTY 360° trial.
- , the authors note that among patients with symptomatic lower extremity PAD undergoing endovascular revascularization, initial treatment costs and total 2-year costs varied significantly according to clinical and lesion-level characteristics, as well as symptom burden.
- These data are especially compelling in the context of cost analyses showing that the durable patient outcomes from the use of orbital atherectomy resulted in lower mean cumulative PAD-related costs one- and two-years after the procedure.
Cardiovascular Systems, a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that a new article published in the Journal of Medical Economicsreviews the two-year PAD-related health care costs of patients enrolled in the LIBERTY 360° trial.
LIBERTY 360° represents the largest, contemporary real-world experience with various endovascular strategies across the full range of Rutherford Class (RC) patients, including those with critical limb ischemia, the most compromised RC6 patients.
In the article, “Two-year PAD-related health care costs in patients undergoing lower extremity endovascular revascularization: results from the LIBERTY 360° trial” by Elizabeth A. Magnuson, et al., the authors note that among patients with symptomatic lower extremity PAD undergoing endovascular revascularization, initial treatment costs and total 2-year costs varied significantly according to clinical and lesion-level characteristics, as well as symptom burden.
Said Scott Ward, CSI’s Chairman, President and Chief Executive Officer, “Data from the LIBERTY 360° study revealed high freedom from major amputation out to three years (RC2-3, 98.5%; RC4-5, 94.0%; and RC6, 79.9%). And the orbital atherectomy sub analysis of this data indicated high freedom from major amputation (RC2-3, 100%; RC4-5, 95.3%; and RC6, 88.6%) with no additional amputations reported after the two-year visit. These data are especially compelling in the context of cost analyses showing that the durable patient outcomes from the use of orbital atherectomy resulted in lower mean cumulative PAD-related costs one- and two-years after the procedure.”
LIBERTY 360° (OAS RC2-6) 2-Year Costs
Orbital atherectomy (RC2-6; N=503) mean index procedure cost was $11,729 and by two-years the mean costs were $29,474, numerically lower than the overall LIBERTY (RC2-6; N=1189) mean two-year cost of $30,491.
|
PAD-related costs ($) up to 2 years following the index procedure |
||||||
|
|
All Patients |
Any Orbital |
|
|
All Patients |
Any Orbital |
|
Index Hospitalization |
11,621 (11,189 to 12,081) |
11,729 (11,165 to 12,443) |
|
Years 1+2 follow-up |
18,870 (17,046 to 20,802) |
17,745 (15,113 to 20,835) |
|
Year 1 follow-up |
11,741 (10,597 to 12,974) |
10,976 (9,344 to 12,741) |
|
|||
|
Endovascular procedures |
7,476 (6,730 to 8,263) |
6,911 (5,758 to 8,127) |
|
Endovascular procedures |
11,465 (10,321 to 12,688) |
10,806 8,944 to 12,916) |
|
Surgical procedures |
1,625 1,218 to 2,041) |
1,698 (1,096 to 2,384) |
|
Surgical procedures |
2,077 (1,616 to 2,569) |
1,987 (1,353 to 2,708) |
|
Other PAD hospitalizations |
140 (74 to 211) |
115 (34 to 231) |
|
Other PAD hospitalizations |
193 (113 to 278) |
128 (41 to 251) |
|
Outpatient/ chronic care |
2,501 (2,011 to 3,000) |
2,253 (1,586 to 3,126) |
|
Outpatient/ chronic care |
5,134 (4,041 to 6,253) |
4,824 (3,272 to 6,791) |
|
Cumulative 1-year |
23,362 (22,110 to 24,623) |
22,706 (20,998 to 24,627) |
|
Cumulative 2-year |
30,491 (28,569 to 32,506) |
29,474 (26,655 to 32,665) |
Magnuson EA, et al. J Med Econ. 2021 April 18:1
